Navigation Links
Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
Date:9/2/2008

s and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.

Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive Dyskinesia (TD). The risk of developing TD increases as the duration of treatment. If signs and symptoms of TD are observed a dose reduction or discontinuation should be considered and it should be noted that the symptoms can temporally deteriorate or even rise after discontinuation.

Other potentially serious adverse events include low blood pressure, seizures, elevated prolactin levels, elevated liver enzymes, thromobembolism, neutopenia, sweating, insomnia, tremor, anxiety, nausea, or vomiting.

Olanzapine should not be used in patients who have a hypersensitivity to the drug nor those with narrow angle glaucoma. It should not be used to treat dementia-related psychosis and/or behavioural disturbances because of an observed increase in death and cerebrovascular accident. It should also not be used in the treatment of dopamine agonist associated psychosis in patients with Parkinson's disease.

The most frequently (seen in greater than or equal to 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels, glucosuria, increased appetite, dizziness, akathisia, parkinsonism, dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases, rash, asthenia, fatigue and oedema.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in In
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
5. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
8. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an ... $1 million in 12% per annum short term debt ... an initial drawdown of $500,000, with accrued interest and ... $500,000 with accrued interest and principal repayable in one ... becoming cashflow positive for any calendar month prior to ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ... recently closed a bridge loan financing (the "2009 ... Purchase Agreement (the "Agreement") with Firebird Global Master ... Company sold a convertible promissory note, due June ... US$1,400,000, and issued a warrant to purchase an ...
(Date:12/16/2009)... Dec. 16 Cohera Medical Inc. today ... a study of its lead surgical adhesive product, ... milestone in the company,s progression of the lead ... investigation is a prospective, open-label, randomized study to ... on wound drainage and associated complications in abdominoplasty, ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 1Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 3American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Successful Disease Management Programs Can Play Role in Health Care Reform 48168 1Successful Disease Management Programs Can Play Role in Health Care Reform 48168 2Successful Disease Management Programs Can Play Role in Health Care Reform 48168 3Successful Disease Management Programs Can Play Role in Health Care Reform 48168 4Successful Disease Management Programs Can Play Role in Health Care Reform 48168 5Successful Disease Management Programs Can Play Role in Health Care Reform 48168 6
... then Expected MCI Prevalence Shows Urgent Need for,Better ... studies related to,experimental Alzheimer,s therapies reported positive results ... Alzheimer,s,Disease (ICAD 2008) in Chicago., One Phase ... early,abnormal brain changes in a protein called "tau" ...
... specialty to benefit from single port surgery with RealHand HD ... ... Systems,announced the successful completion of the first pediatric single port,splenectomy, using RealHand ... very well and one day after his surgery was,sitting up in his ...
Other Medicine Technology:Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 2Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 3Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 4Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 5Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 6Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments 2
(Date:12/17/2009)... MIAMI, Dec. 17 Physicians Healthcare ... , today announced that it has issued ... September 30, 2009. The financials are being posted ... ,, About Physicians Healthcare Management Group, Inc. ... (Phyhealth) is a developer of community-based health maintenance ...
(Date:12/17/2009)... and sociodemographic characteristics involved in the exposure of pregnant ... often work standing up or have to lift heavy ... say they are frequently exposed to some physical risk ... women are especially sensitive to exposure to workplace hazards", ... a researcher at the Higher Centre for Public Health ...
(Date:12/17/2009)... Stem cells that could one day provide therapeutic ... harvested from the tissue of the umbilical cord, just ... cells to treat some blood disorders, said University of ... version of the Journal of Biomedicine and ... be expanded to greater number, are remarkably stable and ...
(Date:12/17/2009)... in Human Resource Development Degree Online , ... ... enrollment has begun for Villanova’s newly online HR master’s ... busy schedules can’t accommodate a campus-based program. With the university’s ... March 2010, location is no longer a barrier to the ...
(Date:12/17/2009)... CareFusion Corporation (NYSE: CFN ) ... unsolicited mini-tender offer by TRC Capital Corporation (TRC) to ... stock, representing approximately 1.8 percent of the shares of ... share is 4.62 percent below the share closing price ... last full trading day prior to the offer. CareFusion ...
Breaking Medicine News(10 mins):Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
... Inc.,(NYSE: SMA ), a leading independent provider of ... markets, announced today that,it will release third quarter financial ... market opens on Wednesday, November 12, 2008.,Symmetry Medical will ... Wednesday, November 12, 2008., A live Web cast ...
... and ... Milk Their Diets, HOUSTON, Oct. 30 The last decade ... seem to go in and out of,fashion like shoulder pads and hemlines. Yet, ... Texas residents --,remain overweight or obese., A new campaign crossing the country, ...
... for Sharing Product, Educational Expertise,with ASCs, ... Medical Inc. (B.,Braun) has launched a new ... and editorial information for ambulatory surgical centers,(ASCs)., ... The new online resource, http://www.asc.bbraunusa.com, ...
... RALEIGH, N.C., Oct. 30 TeleHealth Services, Inc., ... healthcare,market, has named Matthew K. Barker to the ... will include strategic market planning,market research and analysis., ... Mr. Barker,to direct its marketing efforts for its ...
... November 3, 2008, ALEXANDRIA, Va., Oct. 30 ... an amicus brief in support of a,courageous Vermont woman,s ... the amputation of her gangrenous arm caused by the ... the wholehearted backing of the Food and Drug,Administration (FDA), ...
... 30 Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), ... announced the appointment,of William F. Hamilton, Ph.D. to ... audit committee. Dr. Hamilton has over 40 years ... particular expertise in the areas of,technology strategy and ...
Other Medicine News:Health News:Symmetry Medical to Report Third Quarter 2008 Financial Results on November 12, 2008 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:B. Braun Medical Inc. Launches Ambulatory Surgical Center Website 2Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:The Senior Citizens League's Comments on U.S. Supreme Court Case Wyeth v. Levine 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
...
...
...
Medicine Products: